Andrew J. Gartland,Sue Li,John McNevin,Georgia D. Tomaras,Raphael Gottardo,Holly Janes,Youyi Fong,Daryl Morris,Daniel E. Geraghty,Gustavo H. Kijak,Paul T. Edlefsen,Nicole Frahm,Brendan B. Larsen,Sodsai Tovanabutra,Eric Sanders-Buell,Allan C. deCamp,Craig A. Magaret,Hasan Ahmed,Jodie P. Goodridge,Lennie Chen,Philip Konopa,Snehal Nariya,Julia N. Stoddard,Kim Wong,Hong Zhao,Wenjie Deng,Brandon S. Maust,Meera Bose,Shana Howell,Adam Bates,Michelle Lazzaro,Annemarie O'Sullivan,Esther Lei,Andrea Bradfield,Grace Ibitamuno,Vatcharain Assawadarachai,Robert J. O'Connell,Mark S. Desouza,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Merlin L. Robb,John Sidney,Alessandro Sette,Susan Zolla-Pazner,David Montefiorl,M. Juliana McElrath,James I. Mullins,Jerome H. Kim,Peter B. Gilbert,Tomer Hertz

Abstract:ABSTRACT The RV144 HIV-1 vaccine trial demonstrated partial efficacy of 31% against HIV-1 infection. Studies into possible correlates of protection found that antibodies specific to the V1 and V2 (V1/V2) region of envelope correlated inversely with infection risk and that viruses isolated from trial participants contained genetic signatures of vaccine-induced pressure in the V1/V2 region. We explored the hypothesis that the genetic signatures in V1 and V2 could be partly attributed to selection by vaccine-primed T cells. We performed a T-cell-based sieve analysis of breakthrough viruses in the RV144 trial and found evidence of predicted HLA binding escape that was greater in vaccine versus placebo recipients. The predicted escape depended on class I HLA A*02- and A*11-restricted epitopes in the MN strain rgp120 vaccine immunogen. Though we hypothesized that this was indicative of postacquisition selection pressure, we also found that vaccine efficacy (VE) was greater in A*02-positive (A*02 + ) participants than in A*02 − participants (VE = 54% versus 3%, P = 0.05). Vaccine efficacy against viruses with a lysine residue at site 169, important to antibody binding and implicated in vaccine-induced immune pressure, was also greater in A*02 + participants (VE = 74% versus 15%, P = 0.02). Additionally, a reanalysis of vaccine-induced immune responses that focused on those that were shown to correlate with infection risk suggested that the humoral responses may have differed in A*02 + participants. These exploratory and hypothesis-generating analyses indicate there may be an association between a class I HLA allele and vaccine efficacy, highlighting the importance of considering HLA alleles and host immune genetics in HIV vaccine trials. IMPORTANCE The RV144 trial was the first to show efficacy against HIV-1 infection. Subsequently, much effort has been directed toward understanding the mechanisms of protection. Here, we conducted a T-cell-based sieve analysis, which compared the genetic sequences of viruses isolated from infected vaccine and placebo recipients. Though we hypothesized that the observed sieve effect indicated postacquisition T-cell selection, we also found that vaccine efficacy was greater for participants who expressed HLA A*02, an allele implicated in the sieve analysis. Though HLA alleles have been associated with disease progression and viral load in HIV-1 infection, these data are the first to suggest the association of a class I HLA allele and vaccine efficacy. While these statistical analyses do not provide mechanistic evidence of protection in RV144, they generate testable hypotheses for the HIV vaccine community and they highlight the importance of assessing the impact of host immune genetics in vaccine-induced immunity and protection. (This study has been registered at ClinicalTrials.gov under registration no. NCT00223080.)

Infectious Virion Capture by HIV-1 Gp120-Specific IgG from RV144 Vaccinees

Virion Capture by HIV-1 gp 120-Specific IgG from RV 144 Vaccinees

Vaccine Induction of Antibodies Against a Structurally Heterogeneous Site of Immune Pressure Within HIV-1 Envelope Protein Variable Regions 1 and 2

Vaccine-Induced Plasma Iga Specific for the C1 Region of the Hiv-1 Envelope Blocks Binding and Effector Function of Igg

Immune-correlates Analysis of an HIV-1 Vaccine Efficacy Trial.

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

Vaccine-induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection.

HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities

Increased HIV-1 Vaccine Efficacy Against Viruses with Genetic Signatures in Env-V2

Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen is Enhanced by a Gp120 N-terminal Deletion.

Boosting of HIV Envelope CD4 Binding Site Antibodies with Long Variable Heavy Third Complementarity Determining Region in the Randomized Double Blind RV305 HIV-1 Vaccine Trial

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants.

Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an Hiv-1 Vaccine Efficacy Trial Preferentially Use the Vh1 Gene Family

Immunogenicity Of Nyvac Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination And Simian-Human Immunodeficiency Virus Challenge Of Nonhuman Primates

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.

Recombinant MVA-prime Elicits Neutralizing Antibody Responses by Inducing Antigen-Specific B Cells in the Germinal Center

Antibody Light-Chain-restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial is Phylogenetically Conserved.

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis

Vaccine-induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon after Vaccination.

Fcgr2c Polymorphisms Associate with Hiv-1 Vaccine Protection in Rv144 Trial

Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial.